3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes

Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes

Clinical enzymology measures the catalytic activity (or mass) of enzymes released from injured tissue. The board expects you to know the kinetics that make enzyme assays work, the time course of cardiac biomarkers, and the patterns that separate hepatocellular injury, cholestasis, bone disease, and pancreatitis. Endocrinology and toxicology, which share the Clinical Chemistry endocrine-and-toxicology blueprint area, are covered in the next two sections, and bilirubin and ammonia are covered in the liver function section.

---

1. Principles of Clinical Enzymology

Enzymes are biological catalysts that accelerate chemical reactions without being consumed, functioning by lowering the free activation energy ($\Delta G^\ddagger$) required to convert substrate ($S$) into product ($P$): $E + S \xrightleftharpoons[k_{-1}]{k_1} [ES] \xrightarrow{k_2} E + P$

Michaelis-Menten Kinetics: First-Order vs. Zero-Order

The mathematical relationship between substrate concentration $[S]$ and reaction velocity ($V$) is described by the Michaelis-Menten equation: $V = \frac{V_{\max} [S]}{K_m + [S]}$ Where:

• $V_{\max}$ is the maximum achievable reaction velocity when all enzyme catalytic sites are saturated with substrate.
• $K_m$ (Michaelis constant) is the substrate concentration at which the reaction velocity is half-maximal ($\frac{1}{2} V_{\max}$), reflecting enzyme-substrate affinity.

   Reaction Velocity (V)
          |
   Vmax --+ - - - - - - - - - - - - - - - - - - - - - - - - - - - - ZERO-ORDER KINETICS
          |                                   ..............    ([S] >> Km; Rate depends
          |                             . '                     solely on [Enzyme])
   1/2Vmax| - - - - - - - - - - - . '
          |                  . '
          |              . '
          |          . '  FIRST-ORDER KINETICS
          |      . '      ([S] << Km; Rate depends on [Substrate])
          |  . '
          +-------------------+---------------------------------> Substrate Concentration [S]
          0                  Km

1. First-Order Kinetics ($[S] \ll K_m$): At low substrate concentrations, $[S]$ in the denominator is negligible compared to $K_m$, simplifying the equation to $V \approx (V_{\max} / K_m) [S]$. Here, the reaction rate is directly proportional to substrate concentration. First-order kinetics are used in assays designed to measure substrate concentration (e.g., measuring serum glucose via hexokinase or measuring urea via urease).
2. Zero-Order Kinetics ($[S] \gg K_m$): In diagnostic enzymology, the analytical goal is to measure enzyme activity, not substrate. Assays are engineered with substrate present in vast excess (typically $[S] \ge 10-100 \times K_m$). Under these saturated conditions, $K_m + [S] \approx [S]$, simplifying the equation to $V = V_{\max}$. Because all catalytic active sites are constantly saturated, the reaction velocity is independent of substrate concentration and is directly proportional to the active enzyme concentration in patient serum.

Units of Enzyme Activity

Because circulating enzymes exist in minute mass quantities with variable specific activities, clinical laboratories quantify catalytic activity rather than absolute mass concentration:

• International Unit (IU): The quantity of enzyme that catalyzes the conversion of $1.0\text{ }\mu\text{mol}$ of substrate to product per minute under specified, standardized conditions of temperature ($37^\circ\text{C}$), pH, and substrate excess ($1\text{ IU} = 1\text{ }\mu\text{mol/min}$). Concentrations are reported as IU/L or U/L.
• Katal (kat): The SI unit of catalytic activity, defined as the quantity of enzyme catalyzing the conversion of $1.0\text{ mole}$ of substrate per second ($1.0\text{ kat} = 1.0\text{ mol/s}$). Conversion: $1\text{ IU} = 16.67\text{ nkat}$.

Isoenzymes and Isoforms

Isoenzymes are physically distinct forms of an enzyme that catalyze the same biochemical reaction but differ in primary amino acid structure, electrophoretic mobility, immunological reactivity, and tissue distribution. Isoenzymes arise from distinct genetic loci or alternative splicing, whereas isoforms represent post-translational modifications of a specific isoenzyme.

---

2. Cardiac Biomarkers in Acute Coronary Syndrome and Heart Failure

+---------------------------------------------------------------------------------------+
|                         ACUTE MYOCARDIAL INFARCTION BIOMARKER TIMELINE                |
+-------------------+---------------+-------------------+-------------------------------+
| BIOMARKER         | INITIAL RISE  | PEAK ELEVATION    | DURATION TO NORMALIZATION     |
+-------------------+---------------+-------------------+-------------------------------+
| Myoglobin         | 1 - 3 hours   | 6 - 8 hours       | 24 hours                      |
+-------------------+---------------+-------------------+-------------------------------+
| Cardiac Troponin I| 3 - 6 hours   | 12 - 24 hours     | 7 - 10 days                   |
| (cTnI)            |               |                   |                               |
+-------------------+---------------+-------------------+-------------------------------+
| Cardiac Troponin T| 3 - 6 hours   | 12 - 24 hours     | 10 - 14 days                  |
| (cTnT)            |               |                   |                               |
+-------------------+---------------+-------------------+-------------------------------+
| CK-MB             | 4 - 6 hours   | 18 - 24 hours     | 48 - 72 hours                 |
| (Mass / Activity) |               |                   | (Ideal for reinfarction)      |
+-------------------+---------------+-------------------+-------------------------------+
| Total CK          | 4 - 8 hours   | 24 - 36 hours     | 3 - 4 days                    |
+-------------------+---------------+-------------------+-------------------------------+
| LD-1 > LD-2 Flip  | 10 - 24 hours | 48 - 72 hours     | 10 - 14 days                  |
| (Historical)      |               |                   | (Obsolete)                    |
+-------------------+---------------+-------------------+-------------------------------+

Cardiac Troponins (cTnI and cTnT)

The troponin complex regulates calcium-mediated actin-myosin contraction in striated muscle, comprising three subunits:

• Troponin C (TnC): Calcium-binding subunit (identical in skeletal and cardiac muscle; not used clinically).
• Troponin I (TnI): Inhibitory subunit; possesses a unique 31-amino-acid N-terminal sequence expressed exclusively in myocardium (cardiac Troponin I, cTnI).
• Troponin T (TnT): Tropomyosin-binding subunit; expressed in myocardium with minor cross-reactivity in diseased skeletal muscle (cardiac Troponin T, cTnT).

Clinical Profile: Cardiac troponins are the undisputed gold standard for evaluating acute coronary syndromes (ACS). Following myocardial necrosis, troponins begin rising in peripheral blood within 3 to 6 hours, reach a peak at 12 to 24 hours, and remain diagnostically elevated for 7 to 10 days (cTnI) and up to 10 to 14 days (cTnT). High-sensitivity troponin assays (hs-cTn) detect minute elevations within 1 to 3 hours, allowing rapid rule-in and rule-out algorithms.

Creatine Kinase (CK) and CK-MB Isoenzyme

Creatine kinase (CK) is a dimeric enzyme ($82\text{ kDa}$) catalyzing the reversible phosphorylation of creatine by ATP. It exists as three cytoplasmic isoenzymes composed of two polypeptide subunits: M (muscle) and B (brain):

1. CK-BB (CK-1): Brain, prostate, gastrointestinal tract, and bladder. Migrates fastest toward the anode on electrophoresis. Rarely elevated in serum except in extensive bowel infarction, CNS damage, or small cell carcinoma.
2. CK-MB (CK-2): Cardiac muscle (comprises 15-20% of total cardiac CK; skeletal muscle contains <2-3%). Migrates with intermediate mobility.
3. CK-MM (CK-3): Skeletal muscle (comprises 97-99% of skeletal muscle CK) and myocardium (comprises 80% of cardiac CK). Migrates slowest (closest to cathode).

Diagnostic Utility of CK-MB: CK-MB rises within 4 to 6 hours post-AMI, peaks at 18 to 24 hours, and returns to baseline within 48 to 72 hours. Because troponins remain elevated for up to two weeks, they cannot identify recurrent ischemic injury occurring a few days after an index infarction. Classic board teaching names CK-MB as the marker for detecting reinfarction (early recurrent myocardial infarction) occurring 3 to 7 days after an initial event, because an abrupt re-elevation of CK-MB stands out against its normalized baseline. Current universal-definition criteria also accept a fresh rise of more than 20% in serial high-sensitivity troponin values as evidence of reinfarction.

• CK-MB Relative Index (CKI): Differentiates cardiac injury from massive skeletal muscle trauma: $\text{CK-MB Relative Index (\%)} = \frac{\text{CK-MB Mass [ng/mL]}}{\text{Total CK Activity [U/L]}} \times 100$
  • Index < 2.5-3.0%: Skeletal muscle damage.
  • Index > 3.0-5.0%: Definitive myocardial injury.

Myoglobin

Myoglobin is a small cytoplasmic heme protein ($17.8\text{ kDa}$) found in skeletal and cardiac muscle. Due to its low molecular weight, it is released rapidly upon myocyte membrane injury, rising within 1 to 3 hours, peaking at 6 to 8 hours, and clearing via renal excretion within 24 hours. While it lacks cardiac specificity (elevated in skeletal muscle trauma, intramuscular injections, and renal failure), myoglobin possesses an exceptional negative predictive value: a normal myoglobin level at 3 to 4 hours post-chest pain virtually rules out acute myocardial infarction.

Natriuretic Peptides in Congestive Heart Failure (CHF)

• B-Type Natriuretic Peptide (BNP) and NT-proBNP: Synthesized by ventricular cardiomyocytes as pre-proBNP in response to increased ventricular wall tension, diastolic stretch, and volume overload. Cleaved into inactive NT-proBNP (76 amino acids, half-life $\approx 70\text{ minutes}$, cleared renally) and active BNP (32 amino acids, half-life $\approx 20\text{ minutes}$, cleared via neutral endopeptidases and natriuretic peptide receptors).
• Diagnostic Cutoffs for Heart Failure:
  • BNP: $<100\text{ pg/mL}$ rules out CHF (high negative predictive value); $>400\text{ pg/mL}$ strongly indicates acute heart failure.
  • NT-proBNP: $<300\text{ pg/mL}$ rules out CHF; age-stratified rule-in cutoffs: $>450\text{ pg/mL}$ (age $<50$), $>900\text{ pg/mL}$ (age $50-75$), and $>1800\text{ pg/mL}$ (age $>75$).

---

3. Hepatobiliary and Pancreatic Enzymes

Aminotransferases: AST and ALT

• Aspartate Aminotransferase (AST / SGOT): Catalyzes the transfer of an amino group between L-aspartate and $\alpha$-ketoglutarate to form oxaloacetate and glutamate. Found in both cytoplasm (30%) and mitochondria (70%) of hepatocytes, cardiac myocytes, skeletal muscle, kidneys, and erythrocytes.
• Alanine Aminotransferase (ALT / SGPT): Catalyzes the transfer of an amino group between L-alanine and $\alpha$-ketoglutarate to form pyruvate and glutamate. ALT is purely cytoplasmic and localized primarily in hepatocytes, making it far more liver-specific than AST.

The De Ritis Ratio (AST/ALT)

• Normal De Ritis Ratio: $\approx 0.8 - 1.0$.
• Ratio < 1.0 (ALT > AST): Characteristic of acute viral hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), acute biliary obstruction, and toxic exposure. In viral hepatitis, both enzymes reach $>10-50 \times$ the upper limit of normal (ULN), with ALT exceeding AST.
• Ratio > 2.0 (AST > ALT by at least 2:1): Highly suggestive of alcoholic liver disease / alcoholic hepatitis. Mechanisms:
  1. Alcohol induces preferential injury to hepatocyte mitochondria, releasing mitochondrial AST.
  2. Pyridoxal-5'-phosphate (vitamin $B_6$, an essential cofactor for both enzymes) is depleted in chronic alcoholism; this deficiency inhibits ALT apoenzyme synthesis far more severely than AST synthesis.
• Ratio > 1.0 in Non-Alcoholic Disease: When an established chronic liver disorder (e.g., chronic hepatitis C) transitions from mild hepatitis to advanced hepatic cirrhosis, the De Ritis ratio flips from $<1.0$ to $>1.0$ due to impaired sinusoidal clearance of AST by hepatic endothelial cells.

Alkaline Phosphatase (ALP) and Gamma-Glutamyltransferase (GGT)

• Alkaline Phosphatase (ALP): Zinc and magnesium metalloenzyme that hydrolyzes monophosphate esters at an alkaline optimal pH ($9.0-10.5$). Localized in the microvillar membranes of bile canaliculi, bone osteoblasts, intestinal mucosa, and the placenta.
  • Clinical Indications: Marked elevations ($>3-10 \times$ ULN) occur in cholestasis/biliary obstruction (cholelithiasis, pancreatic head adenocarcinoma) and osteoblastic bone diseases (Paget disease of bone, osteosarcoma, healing fractures, rickets/osteomalacia, osteoblastic bone metastases from prostate cancer). Physiological elevations occur during normal third-trimester pregnancy (placental ALP) and adolescent growth spurts (bone ALP).
• Differentiating ALP Isoenzymes by Heat Stability: Serum is incubated at $56^\circ\text{C}$ for 10 minutes before testing (remember: "Bone burns, Liver lives"):
  • Placental ALP (Regan/Nagao isoenzyme): Extremely heat-stable; resists denaturation even at $65^\circ\text{C}$.
  • Intestinal ALP: Intermediate stability (50-60% inactivated).
  • Liver ALP: Moderately stable (50-70% activity remains at $56^\circ\text{C}$).
  • Bone ALP: Most heat-labile; $>80-90\%$ denatured/destroyed at $56^\circ\text{C}$ (<20% residual activity).
• Differentiating Bone vs. Liver ALP Using GGT:
  • Gamma-Glutamyltransferase (GGT): Membrane-bound enzyme transferring glutamyl groups from peptides to amino acids. GGT is abundant in biliary canalicular epithelial cells, kidney, and pancreas, but is completely absent from bone and placenta.
  • Diagnostic Matrix:
    • $\uparrow \text{ALP} + \uparrow \text{GGT} \longrightarrow$ Hepatobiliary source (cholestasis, biliary obstruction).
    • $\uparrow \text{ALP} + \text{Normal GGT} \longrightarrow$ Bone etiology (Paget disease, osteosarcoma, rickets) or physiological pregnancy.
  • GGT as Alcohol Biomarker: GGT is induced by hepatic microsomal enzyme stimulation; it is a sensitive screening marker for chronic alcohol consumption and tracks therapeutic compliance during alcohol cessation.

Pancreatic Enzymes: Amylase and Lipase

• Amylase (AMS): Hydrolase that cleaves $\alpha$-1,4-glucosidic bonds in starch and glycogen. Consists of two isoenzyme families: P-type (pancreatic) and S-type (salivary). In acute pancreatitis, serum amylase rises within 2 to 12 hours, peaks at 24 hours, and normalizes rapidly within 3 to 5 days.
  • Macroamylasemia: Benign condition where amylase complexes with circulating immunoglobulins (IgA or IgG) to form a high-molecular-weight macromolecule ($>200\text{ kDa}$) that cannot pass through the renal glomerular filtration barrier. Characterized by persistently elevated serum amylase accompanied by abnormally low urine amylase and a low amylase-to-creatinine clearance ratio ($\text{ACCR} < 1\%$, normal $2-5\%$): $\text{ACCR (\%)} = \frac{\text{Urine Amylase} \times \text{Serum Creatinine}}{\text{Serum Amylase} \times \text{Urine Creatinine}} \times 100$
• Lipase (LPS): Hydrolyzes glycerol esters of long-chain fatty acids in the presence of colipase and bile salts. Lipase is superior to amylase for diagnosing acute pancreatitis because it is virtually specific to pancreatic acinar tissue (salivary glands produce no lipase), rises within 4 to 8 hours, peaks at 24 hours, and remains elevated for 8 to 14 days, providing an extended diagnostic window in patients presenting days after pain onset.

---

4. Diagnostic Enzyme Profile Summary